Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations
about
Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogensIn vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centersIn vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocciUpdate on clinical significance of coagulase-negative staphylococciUse of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity dataSusceptibility of Staphylococcus species and subspecies to teicoplanin.Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calciumIn vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.A closer look at vancomycin, teicoplanin, and antimicrobial resistance.Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci.Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.
P2860
Q33981048-3EB00752-03EB-466A-AE3B-600588A50C7FQ33982424-1069FE4F-3371-492F-AA4A-114024C7C64BQ35128490-6A79AA91-EF66-4729-BBF5-8EBC80AAA941Q35361659-FD05DE12-6AC3-4715-94C7-072D04E74773Q36640978-38FF49CC-AC5C-4F92-AE5C-9DB7CB4A6A48Q36751113-926A6640-D474-48C2-A12D-81B62A009D03Q36754998-78120C57-DA9B-4537-8D21-9CB40D19A7E2Q39865308-21424B5F-752F-43A7-8E30-EE05FDD56BC4Q40088863-7B2D1C34-C3AB-4461-BB2C-F6D24C188562Q41646436-832A5438-A071-4E2E-8859-4B687A6F431DQ54216097-76A0C40B-8B96-4078-BDE0-FF601AD383A1Q54331647-382912A0-2890-4AA0-A850-9AC0E21CBA1B
P2860
Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations
description
1989 nî lūn-bûn
@nan
1989 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Activities of daptomycin and t ...... bility testing recommendations
@ast
Activities of daptomycin and t ...... bility testing recommendations
@en
type
label
Activities of daptomycin and t ...... bility testing recommendations
@ast
Activities of daptomycin and t ...... bility testing recommendations
@en
prefLabel
Activities of daptomycin and t ...... bility testing recommendations
@ast
Activities of daptomycin and t ...... bility testing recommendations
@en
P2093
P2860
P356
P1476
Activities of daptomycin and t ...... bility testing recommendations
@en
P2093
P2860
P304
P356
10.1128/AAC.33.4.585
P407
P577
1989-04-01T00:00:00Z